2006
The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia
Krystal JH, D’Souza D, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, Pearlson G. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotoxicity Research 2006, 10: 235-252. PMID: 17197373, DOI: 10.1007/bf03033360.Peer-Reviewed Original ResearchConceptsSubstance abuse riskSubstance abuseSubstance abuse disordersAbuse riskSubstances of abuseNicotinic cholinergicPatient groupDopaminergic inputAbused substancesAbuse disordersSchizophrenic patientsDysphoric effectsAbuse liabilityHigh dosesLow dosesNegative symptomsReceptor functionAltered responseSchizophreniaSchizophrenic individualsRiskReward processingSubjective distressImpulsive behaviorDoses
2005
Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence
Perry E, Gil R, Miles D, Brenner L, Macdougall L, Johnson R, Degen K, Gueorguieva R, Petrakis I, Krystal J, D'Souza D. Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. Journal Of Dual Diagnosis 2005, 1: 37-47. DOI: 10.1300/j374v01n01_04.Peer-Reviewed Original ResearchCocaine abusePsychiatric symptomsCocaine cravingCatecholamine reuptake inhibitorCurrent antipsychotic medicationsCocaine consumptionPlacebo groupAntipsychotic pharmacotherapyReuptake inhibitorsAntipsychotic medicationAntipsychotic treatmentComorbid schizophreniaSchizoaffective patientsSubstance abuse issuesSchizophrenic patientsPatientsSchizoaffective disorderSchizophrenia patientsNatural historyMazindolPilot studyGroup therapySchizophreniaSymptomsAbuse issues
2002
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms
Abi-Saab W, Seibyl JP, D'Souza C, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology 2002, 162: 55-62. PMID: 12107618, DOI: 10.1007/s00213-002-1057-7.Peer-Reviewed Original ResearchConceptsReceptor antagonismSchizophrenic patientsNeuroleptic-free schizophrenic patientsBrief Psychiatric Rating ScaleDouble-blind conditionsPsychiatric Rating ScaleTest dayRitanserin pretreatmentIntravenous infusionReceptor modulationAntipsychotic activityMale inpatientsReceptor stimulationPlasma prolactinCortisol levelsSchizoaffective disorderSchizophrenia symptomsPositive symptomsNegative symptomsRandomized orderPatientsRating ScaleBehavioral activationSymptomsRitanserin
2001
A neurobiological basis for substance abuse comorbidity in schizophrenia
Chambers R, Krystal J, Self D. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry 2001, 50: 71-83. PMID: 11526998, PMCID: PMC2913410, DOI: 10.1016/s0006-3223(01)01134-9.Peer-Reviewed Original ResearchConceptsDrug rewardLong-term substance abuseMedication side effectsPrior drug exposureSubstance abuse comorbidityNeuropathology of schizophreniaPrimary disease symptomsAddictive behaviorsDrug-seeking behaviorHippocampal dysfunctionDrug exposureFrontal cortexNucleus accumbensHippocampal formationSchizophrenic patientsSide effectsCognitive impairmentNegative symptomsSubstance abuseAltered integrationNeural circuitrySymptomsSchizophreniaMotivational changesComorbidities
2000
401. One Hertz rTMS of left temporoparietal cortex in schizophrenic patients reporting auditory hallucinations
Hoffman R, Boutros N, Berman R, Hu S, Rachid F, Schaffer N, Krystal J, Charney D. 401. One Hertz rTMS of left temporoparietal cortex in schizophrenic patients reporting auditory hallucinations. Biological Psychiatry 2000, 47: s122-s123. DOI: 10.1016/s0006-3223(00)00670-3.Peer-Reviewed Original Research
1999
Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated “voices”
Hoffman R, Boutros N, Berman R, Roessler E, Belger A, Krystal J, Charney D. Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated “voices”. Biological Psychiatry 1999, 46: 130-132. PMID: 10394483, DOI: 10.1016/s0006-3223(98)00358-8.Peer-Reviewed Original ResearchConceptsTranscranial magnetic stimulationLow-frequency transcranial magnetic stimulationFrequency transcranial magnetic stimulationAuditory hallucinationsMagnetic stimulationTemporoparietal cortexSham stimulationPersistent auditory hallucinationsCross-over designSpeech perception areasHertz stimulationCerebral cortexSchizophrenic patientsCortical activationHallucination severityPatientsActive stimulationTotal cessationCortexStimulationHallucinationsGreater improvementActivationPrior studiesSeverityNo Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia
Abi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, Baldwin R, Seibyl J, Mawlawi O, de Erasquin G, Charney D, Innis R. No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia. Neuropsychopharmacology 1999, 20: 650-661. PMID: 10327433, DOI: 10.1016/s0893-133x(98)00107-9.Peer-Reviewed Original ResearchConceptsReceptor densitySchizophrenic patientsVivo benzodiazepine receptor bindingBDZ receptor densityMale schizophrenic patientsBenzodiazepine receptor densityPathophysiology of schizophreniaBenzodiazepine receptor bindingSingle photon emissionRegional distribution volumesPrevious postmortemGABA transmissionBDZ antagonistBDZ receptorsReceptor expressionNeurotransmitter systemsHealthy volunteersPsychotic symptomsBrain regionsDistribution volumeReceptor bindingSchizophreniaVivo studiesPatientsPossible alterationsToward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness
1998
Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M. Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort. American Journal Of Psychiatry 1998, 155: 761-767. PMID: 9619147, DOI: 10.1176/ajp.155.6.761.Peer-Reviewed Original ResearchConceptsD2 receptor availabilityAcute amphetamine challengeStriatal dopamine transmissionAmphetamine challengeReceptor availabilityDopamine releaseHealthy subjectsDopamine transmissionDopamine D2 receptor availabilityExcess dopamine releaseStriatal dopamine releaseComparison groupD2 receptor radiotracerHistory of alcoholDSM-IV criteriaSingle photon emissionNew cohortUntreated patientsReceptor radiotracerSchizophrenic patientsPatientsSecond cohortParental socioeconomic statusPositive symptomsSubstance abuse
1996
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 9235-9240. PMID: 8799184, PMCID: PMC38625, DOI: 10.1073/pnas.93.17.9235.Peer-Reviewed Original ResearchConceptsAmphetamine-induced dopamine releaseDopamine releaseDopaminergic transmissionPsychotic symptomsSchizophrenic groupDopamine D2 receptor availabilityAmphetamine-induced decreaseAmphetamine-induced reductionD2 receptor availabilityD2 receptor radiotracerPositive psychotic symptomsSingle photon emissionExaggerated stimulationAbnormal responsivenessDopaminergic neuronsHealthy controlsReceptor radiotracerSchizophrenic patientsDopamine hypothesisDopamine functionReceptor availabilityAmphetamine effectsControl groupSchizophrenic subjectsSchizophreniaSPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia
Laruelle M, Abi-Dargham A, Gil R, van Dyck C, Erdos J, D'Souza D, Rosenblatt W, McCance-Katz E, Zea-Ponce Y, Zoghbi S, Baldwin R, Hoffer P, Krystal J, Charney D, Innis R. SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia. Schizophrenia Research 1996, 18: 198-199. DOI: 10.1016/0920-9964(96)85619-2.Peer-Reviewed Original Research
1993
Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. American Journal Of Psychiatry 1993, 150: 1408-1410. PMID: 8102512, DOI: 10.1176/ajp.150.9.1408.Peer-Reviewed Original ResearchConceptsNeuroleptic-free schizophrenic patientsInterleukin-2Dopaminergic neurotransmissionSchizophrenic patientsElevated CSF levelsAbnormal brain morphologyInterleukin-1 alphaAutoimmune phenomenaCSF levelsHealthy subjectsBrain morphologyPatientsElevated levelsNeurotransmissionCell growthAutoimmunityLevelsSchizophreniam-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients: Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia
Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS. m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients: Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia. JAMA Psychiatry 1993, 50: 624-635. PMID: 8102048, DOI: 10.1001/archpsyc.1993.01820200034004.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleHealthy subjectsPsychiatric Rating ScalePositive symptomsSchizophrenic patientsPatient groupDouble-blind randomized comparisonVeterans Affairs Medical CenterRating ScaleNeuroleptic-free schizophrenic patientsFirst patient groupSerotonin partial agonistPrincipal outcome variableVisual analog scaleBaseline prolactin levelsHigher baseline levelsSymptoms of schizophreniaAnalog scaleRandomized comparisonAnxiogenic responseSum of scoresProlactin levelsSerotonergic systemSerotonin functionHormone levelsEffects of Cocaine on Hospital Course in Schizophrenia
SEIBYL J, SATEL S, ANTHONY D, SOUTHWICK S, KRYSTAL J, CHARNEY D. Effects of Cocaine on Hospital Course in Schizophrenia. The Journal Of Nervous And Mental Disease 1993, 181: 31-37. PMID: 8093475, DOI: 10.1097/00005053-199301000-00006.Peer-Reviewed Original ResearchConceptsSubstance useSuicidal ideationCocaine useLifetime drug use historyAvailable hospital recordsHigher hospitalization ratesHigher neuroleptic dosesNon-using patientsEffects of cocainePoor illness courseDrug use historySubstance use patternsHigh rateSchizophrenia clinicHospital courseNeuroleptic doseHospital recordsHospitalization ratesIllness courseInpatient chartsNeuroleptic dosesPsychiatric hospitalizationNeuroleptic dosingHospitalizationSchizophrenic patients
1992
Startle gating deficits occur across prepulse intensities in schizophrenic patients
Grillon C, Ameli R, Charney D, Krystal J, Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biological Psychiatry 1992, 32: 939-943. PMID: 1467378, DOI: 10.1016/0006-3223(92)90183-z.Peer-Reviewed Original ResearchConceptsPrepulse inhibitionPrepulse stimulusSchizophrenic patientsStartle reflexControl groupStartle gating deficitsCentral inhibitory mechanismsDeficient prepulse inhibitionGating deficitsStartling stimulusNormal controlsPatientsReflexPrepulse intensityInhibitory mechanismFurther studiesStimuliInhibitionGroup